Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04131634 · ClinicalTrials.gov registry record · Phase 2
Stereotactic Ablative Radiation for Oligo-Progression of Urothelial Cancer
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04131634: Clinical Trial Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
NCT04131634 is a Phase 2 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04131634, a Phase 2 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
To evaluate the benefit of SAbR for oligo-progressive metastatic urothelial cancer.
Primary Outcome
Progression free survival (PFS) at 6 months in the patients for whom SAbR is added to the ICI after progression on ICI. PFS will be defined as the combination of progressive disease from SAbR start date and death from any cause.
Interventions
- RADIATION Stereotactic Ablative Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-01-16 |
| Est. Completion | 2021-06-10 |
| Phase | Phase 2 |
Why NCT04131634 stopped before completion
NCT04131634 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Stereotactic Ablative Radiation is the first listed.
NCT04131634 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04131634 about?
NCT04131634 is a clinical study titled "Stereotactic Ablative Radiation for Oligo-Progression of Urothelial Cancer". To evaluate the benefit of SAbR for oligo-progressive metastatic urothelial cancer.
What is the current status of trial NCT04131634?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2020-01-16. Estimated completion is 2021-06-10.
What interventions are being tested in trial NCT04131634?
The interventions under investigation include: Stereotactic Ablative Radiation (RADIATION).
Who is sponsoring clinical trial NCT04131634?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04131634's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI